Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 July 2020Website:
http://www.nkartatx.comNext earnings report:
21 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 23:41:10 GMTDividend
Analysts recommendations
Institutional Ownership
NKTX Latest News
Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024.
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings.
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.
NKTX has experienced a more than 50% decline from its peak in March 2024. The company is working on developing NKX019, a CAR-NK cell therapy that shows promise in treating cancer and autoimmune disorders. Initial data on NKX019 in oncology has been released, with more data expected in the middle of the year. The company has also begun exploring the potential of NKX019 in treating autoimmune diseases in the first half of 2024.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:
In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors.
What type of business is Nkarta?
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
What sector is Nkarta in?
Nkarta is in the Healthcare sector
What industry is Nkarta in?
Nkarta is in the Biotechnology industry
What country is Nkarta from?
Nkarta is headquartered in United States
When did Nkarta go public?
Nkarta initial public offering (IPO) was on 10 July 2020
What is Nkarta website?
https://www.nkartatx.com
Is Nkarta in the S&P 500?
No, Nkarta is not included in the S&P 500 index
Is Nkarta in the NASDAQ 100?
No, Nkarta is not included in the NASDAQ 100 index
Is Nkarta in the Dow Jones?
No, Nkarta is not included in the Dow Jones index
When was Nkarta the previous earnings report?
No data
When does Nkarta earnings report?
The next expected earnings date for Nkarta is 21 March 2025